CL2013002811A1 - Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion. - Google Patents

Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.

Info

Publication number: CL2013002811A1
Authority: CL; Chile
Prior art keywords: epitope; coagulation; encodes; binds; genetic
Prior art date: 2011-04-01

Application number

CL2013002811A

Other languages

English (en)

Inventor

Zhuozhi Wang

John Murphy

Tobias Marquardt

Dieter Moosmayer

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-01

Filing date

2013-09-30

Publication date

2014-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002811(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-30 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2014-02-28 Publication of CL2013002811A1 publication Critical patent/CL2013002811A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2013002811A 2011-04-01 2013-09-30 Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion. CL2013002811A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161471101P	2011-04-01	2011-04-01

Publications (1)

Publication Number	Publication Date
CL2013002811A1 true CL2013002811A1 (es)	2014-02-28

Family

ID=46932389

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013002811A CL2013002811A1 (es)	2011-04-01	2013-09-30	Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.

Country Status (37)

Country	Link
US (5)	US20140294832A1 (es)
EP (1)	EP2694544B1 (es)
JP (4)	JP6170903B2 (es)
KR (2)	KR20190079698A (es)
CN (2)	CN103797030B (es)
AU (3)	AU2012236296A1 (es)
BR (1)	BR112013025376A2 (es)
CA (2)	CA2831907C (es)
CL (1)	CL2013002811A1 (es)
CO (1)	CO6890074A2 (es)
CR (1)	CR20130499A (es)
CU (1)	CU20130128A7 (es)
CY (1)	CY1121538T1 (es)
DK (1)	DK2694544T3 (es)
DO (1)	DOP2013000218A (es)
EA (2)	EA201991704A3 (es)
EC (1)	ECSP13012913A (es)
ES (1)	ES2722824T3 (es)
GT (1)	GT201300229A (es)
HK (1)	HK1243426A1 (es)
HR (1)	HRP20190467T1 (es)
HU (1)	HUE042706T2 (es)
IL (4)	IL228633B (es)
LT (1)	LT2694544T (es)
MX (1)	MX2013011218A (es)
MY (2)	MY190951A (es)
PE (1)	PE20141149A1 (es)
PH (4)	PH12013502039A1 (es)
PL (1)	PL2694544T3 (es)
PT (1)	PT2694544T (es)
RS (1)	RS58633B1 (es)
SG (2)	SG10201602606UA (es)
SI (1)	SI2694544T1 (es)
TR (1)	TR201905101T4 (es)
UA (1)	UA113623C2 (es)
WO (1)	WO2012135671A2 (es)
ZA (1)	ZA201308169B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010071894A2 (en)	2008-12-19	2010-06-24	Baxter International Inc.	Tfpi inhibitors and methods of use
CA2745317C (en)	2008-12-22	2019-03-05	Ida Hilden	Antibodies against tissue factor pathway inhibitor
SI2542257T1 (en)	2010-03-01	2018-01-31	Bayer Healthcare Llc	Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
AU2011227714B2 (en)	2010-03-19	2014-09-04	Takeda Pharmaceutical Company Limited	TFPI inhibitors and methods of use
TR201905101T4 (tr) *	2011-04-01	2019-05-21	Bayer Healthcare Llc	Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar.
CN109111505A (zh)	2012-03-21	2019-01-01	百深有限责任公司	Tfpi抑制剂及其使用方法
BR112014024373A2 (pt) *	2012-03-30	2017-08-08	Bayer Healthcare Llc	anticorpos regulados por protease
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
JP6586016B2 (ja) *	2013-03-15	2019-10-02	ノヴォノルディスクアー／エス	組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
EP2970497B1 (en)	2013-03-15	2017-10-25	Bayer HealthCare LLC	Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
WO2015007880A1 (en) *	2013-07-19	2015-01-22	Novo Nordisk A/S	Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
JP6783754B2 (ja) *	2014-09-17	2020-11-11	ノヴォノルディスクアー／エス	組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
MY178445A (en) *	2015-02-25	2020-10-13	Mogam Inst Biomedical Res	Novel antibody binding to tfpi and composition comprising the same
WO2017029583A2 (en) *	2015-08-19	2017-02-23	Pfizer Inc.	Tissue factor pathway inhibitor antibodies and uses thereof
JP7444059B2 (ja) *	2018-07-25	2024-03-06	ソニーグループ株式会社	血液凝固系解析装置
CN112442127A (zh) *	2019-08-29	2021-03-05	苏州康宁杰瑞生物科技有限公司	针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06153985A (ja) *	1992-11-16	1994-06-03	Teijin Ltd	モノクローナル抗体
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CA2745317C (en) *	2008-12-22	2019-03-05	Ida Hilden	Antibodies against tissue factor pathway inhibitor
SI2542257T1 (en) *	2010-03-01	2018-01-31	Bayer Healthcare Llc	Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
TR201905101T4 (tr) *	2011-04-01	2019-05-21	Bayer Healthcare Llc	Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar.
US8613919B1 (en) *	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
US9592297B2 (en) *	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations

2012
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en not_active Ceased
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Ceased
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko not_active Expired - Fee Related
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039A1/en unknown
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
2019
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown

Also Published As

Publication number	Publication date
EP2694544A2 (en)	2014-02-12
JP2014511685A (ja)	2014-05-19
ES2722824T3 (es)	2019-08-19
DK2694544T3 (en)	2019-04-15
AU2012236296A1 (en)	2013-10-24
CA3068997A1 (en)	2012-10-04
MY190951A (en)	2022-05-24
CN103797030B (zh)	2017-05-31
CN107090046A (zh)	2017-08-25
US20140294832A1 (en)	2014-10-02
KR20190079698A (ko)	2019-07-05
HRP20190467T1 (hr)	2019-05-03
IL274686B (en)	2021-09-30
PE20141149A1 (es)	2014-08-28
LT2694544T (lt)	2019-04-25
WO2012135671A3 (en)	2012-12-13
PH12013502039B1 (en)	2013-12-16
AU2019201814A1 (en)	2019-04-04
JP2017113019A (ja)	2017-06-29
JP6170903B2 (ja)	2017-07-26
AU2017203105A1 (en)	2017-06-01
PH12019500440A1 (en)	2020-10-12
JP2021019619A (ja)	2021-02-18
CU20130128A7 (es)	2014-03-26
SG10201602606UA (en)	2016-04-28
TR201905101T4 (tr)	2019-05-21
EP2694544B1 (en)	2019-01-23
EA201991704A3 (ru)	2020-06-30
BR112013025376A2 (pt)	2017-07-25
KR101995302B1 (ko)	2019-07-02
MY165499A (en)	2018-03-27
RS58633B1 (sr)	2019-05-31
EA201991704A2 (ru)	2020-03-31
HK1243426A1 (zh)	2018-07-13
US20190194353A1 (en)	2019-06-27
GT201300229A (es)	2014-11-13
CA2831907C (en)	2020-03-24
CA2831907A1 (en)	2012-10-04
CY1121538T1 (el)	2020-05-29
IL274686A (en)	2020-06-30
IL228633A0 (en)	2013-12-31
MX2013011218A (es)	2013-10-17
ZA201308169B (en)	2016-03-30
PL2694544T3 (pl)	2019-07-31
KR20140019428A (ko)	2014-02-14
HUE042706T2 (hu)	2019-07-29
US20220041752A1 (en)	2022-02-10
EP2694544A4 (en)	2015-03-25
IL228633B (en)	2018-03-29
PH12019500439A1 (en)	2020-10-12
CN103797030A (zh)	2014-05-14
WO2012135671A2 (en)	2012-10-04
NZ615969A (en)	2016-01-29
PH12013502039A1 (en)	2013-12-16
SI2694544T1 (sl)	2019-06-28
EA201301107A1 (ru)	2014-11-28
US20170107298A1 (en)	2017-04-20
DOP2013000218A (es)	2013-11-15
IL257145A (en)	2018-03-29
PH12019500441A1 (en)	2020-10-12
JP2018172411A (ja)	2018-11-08
CO6890074A2 (es)	2014-03-10
UA113623C2 (uk)	2017-02-27
CR20130499A (es)	2013-10-24
SG193594A1 (en)	2013-10-30
IL283829A (en)	2021-07-29
EA034214B1 (ru)	2020-01-17
US20180194857A1 (en)	2018-07-12
JP6363747B2 (ja)	2018-07-25
PT2694544T (pt)	2019-04-02
ECSP13012913A (es)	2014-02-28

Similar Documents

Publication	Publication Date	Title
CL2013002811A1 (es)	2014-02-28	Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
CL2012002415A1 (es)	2013-08-23	Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.
CL2011002482A1 (es)	2012-03-30	Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2014000590A1 (es)	2014-10-17	Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.
CL2012001304A1 (es)	2012-08-03	Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas.
CO6410314A2 (es)	2012-03-30	Proteínas de unión a il-17
CL2013000369A1 (es)	2014-08-08	Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2008000935A1 (es)	2008-11-07	Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
CL2014000114A1 (es)	2014-08-18	Anticuerpo que se une a r-espondina 1 humana (rspo1); polipéptido que comprende un anticuerpo; composición farmacéutica que comprende el anticuerpo; uso para inhibor el crecimiento de un tumor.
BR112012022210A2 (pt)	2017-09-05	anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
CL2014003140A1 (es)	2015-02-27	Anticuerpos aislado que se une a ly6e; metodo de produccion; inmunoconjugado que lo contiene; formulacion farmaceutica que lo contiene y métodos de uso.
CL2013001468A1 (es)	2014-03-21	Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
CL2013000930A1 (es)	2014-03-28	Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
CL2008001675A1 (es)	2008-11-21	Dominio variable simple (dab) de inmunoglobulina anti-factorde crecimiento endotelial vascular (vegf); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion;antogonista de vegf que comprende el dab; composicion que comprende antogonista;y uso del antagonista para preparar un medicamento.
CL2014000758A1 (es)	2014-08-22	Anticuerpo aislado o fragmento del mismo que se une especificamente a erbb3; composicion farmaceutica que lo comprende; y su uso para inhibir el crecimiento tumoral.
CL2013002006A1 (es)	2014-05-09	Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto.
BR112013018454A2 (pt)	2017-06-27	"anticorpo anti-p-selectina e seu uso no tratamento ou inibição de doenças trombóticas e inflamatórias, bem como composição que o compreende"
CL2009001155A1 (es)	2010-06-04	Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
CL2013003645A1 (es)	2014-07-11	Anticuerpo monoclonal anti-ax1 (subfamilia tam de receptores tirosina quinasa); fragmento de dicho anticuerpo; vector y célula que la comprenden; composición farmacéutica que lo comprende; uso para tratar cáncer.
BR112013017080A8 (pt)	2023-05-09	Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
CL2013001231A1 (es)	2013-12-20	Anticuerpo anti il-23p19 o su fragmento de union a antigeno; polinucleotido que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar diversas enfermedades.
CL2013001854A1 (es)	2014-03-07	Anticuerpo anti-pcsk9 o un fragmento del mismo que comprende un dominio variable; acido nucleico; vector; celula huesped; metodo de obtencion; composicion farmaceutica; y su uso para tratar hipercolesterolemia en un sujeto.
TH1501005387A (th)	2020-06-08	ไวรัสโรคนิวคาสเซิล และ การใช้ของสิ่งนั้น
DOP2012000266A (es)	2013-01-31	PROTEÍNAS QUE SE UNEN AL TNF-a